Skip to main content
PMC home page
Cancer Immunology, Immunotherapy : CII logoLink to Cancer Immunology, Immunotherapy : CII
. 1990 Mar;31(2):86–92. doi: 10.1007/BF01742371

Mycoplasma capricolum membranes induce tumor necrosis factor α by a mechanism different from that of lipopolysaccharide

Talia Sher 1,✉, Shlomo Rottem 3, Ruth Gallily 1
PMCID: PMC11038233  PMID: 2322937

Abstract

Heat-inactivated (60°C, 45 min)Mycoplasma capricolum strain JR cells activate murine macrophages to secrete high levels of tumór necrosis factor α (TNFα) and to lyse tumor target cells efficiently. Fractionation of the intactM. capricolum cells, obtained from cells harvested at the exponential phase of growth, shows that their capacity to induce TNFα secretion by macrophage resides exclusively in the membrane fraction. The macrophage-mediated cytolysis following activation byM. capricolum membranes was significantly inhibited by specific anti-recombinant murine TNFα antibodies.M. capricolum membranes are a potent inducer of TNFα as the commonly used bacterial lipopolysaccharide, indicated by their doseresponse curve for macrophage activation. Our study further showed thatM. capricolum membranes and lipopolysaccharide synergize to augment TNFα secretion by C57BL/6-derived macrophages markedly. Moreover, lipopolysaccharide-unresponsive C3H/HeJ-derived macrophages, were pronouncedly activated byM. capricolum membranes, which do not contain lipopolysaccharide. These findings suggest that the mechanism by whichM. capricolum membranes activate macrophages differs from that of lipopolysaccharide. Results of preliminary experiments show that human monocytes as well secrete TNFα following activation byM. capricolum membranes. Thus, in contrast with the prohibitive toxicity of lipopolysaccharide to animals and humans,M. capricolum membranes, which contain no lipopolysaccharide and are nontoxic in nature, may be of therapeutic value in the treatment of cancer.

Keywords: Membrane Fraction, Human Monocyte, Macrophage Activation, Tumor Target, Potent Inducer

Footnotes

This study was supported by the Ernst David Bergmann Fund of the Hebrew University, Jerusalem, the Concern II Foundation for Cancer Research, Los Angeles, and the Society of Research Associates of the Lautenberg Center

References

  • 1.Anders W. Production and clearance of tumor necrosis factor in rats exposed to endotoxin and dexamethasone. Clin Immunol Immunopathol. 1987;45:348. doi: 10.1016/0090-1229(87)90087-0. [DOI] [PubMed] [Google Scholar]
  • 2.Bauss F, Dröge W, Männel DA. Tumor necrosis factor mediates endotoxic effects in mice. Infect Immun. 1987;55(7):1622. doi: 10.1128/iai.55.7.1622-1625.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Beutler B, Cerami A. Cachectin and tumor necrosis factor as two sides of the same biological coin. Nature. 1986;320:584. doi: 10.1038/320584a0. [DOI] [PubMed] [Google Scholar]
  • 4.Beutler B, Krochin N, Milsark IW, Luedke C, Cerami A. Control of cachectin (tumor necrosis factor) synthesis: mechanisms of endotoxin resistance. Science. 1986;323:977. doi: 10.1126/science.3754653. [DOI] [PubMed] [Google Scholar]
  • 5.Bloksma N, Van de Wiel PA, Kuper CF, Hofhuis FMA. Tumor necrosis factor/cachectin and related cytokines. Basel: Karger; 1988. Synergy of recombinant tumor necrosis factor and endotoxin against Meth A tumors in vivo and endothelial cells in vitro; p. 171. [Google Scholar]
  • 6.Boyum A. Separation of leukocytes from blood and bone-marrow. Scand J Clin Lab Invest. 1968;21:9. [PubMed] [Google Scholar]
  • 7.Carswell EA, Old LJ, Kassel RL, Green S, Fiore N, Williamson B. An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci USA. 1975;72:3666. doi: 10.1073/pnas.72.9.3666. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Chun M, Hoffmann MK. Combination immunotherapy of cancer in a mouse model: synergism between tumor necrosis factor and other defense systems. Cancer Res. 1987;47:115. [PubMed] [Google Scholar]
  • 9.Decker T, Lohmann-Matthes ML, Gifford GE. Cellassociated tumor necrosis factor (TNF) as a killing mechanism of activated cytotoxic macrophages. J Immunol. 1987;138:962. [PubMed] [Google Scholar]
  • 10.Dietz JN, Cole BC. Direct activation of the J774.1 murine macrophage cell line byMycoplasma arthritidis . Infect Immun. 1982;37:811. doi: 10.1128/iai.37.2.811-819.1982. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Dijkstra J, Mellors JN, Ryan JL, Czoka FC. Modulation of the biological activity of bacterial endotoxin by incorporation into liposomes. J Immunol. 1987;138:2663. [PubMed] [Google Scholar]
  • 12.Elias JA, Gustilo K, Baeder W, Freundlich B. Synergistic stimulation of fibroblast prostaglandin production by recombinant interleukin 1 and tumor necrosis factor. J Immunol. 1987;138:3812. [PubMed] [Google Scholar]
  • 13.Flick DA, Gifford GE. Comparison ofin vitro cell cytotoxic assays for tumor necrosis factor. J Immunol Methods. 1984;68:167. doi: 10.1016/0022-1759(84)90147-9. [DOI] [PubMed] [Google Scholar]
  • 14.Gabridge MG, Chandler DKF, Daniels MJ. The mycoplasmas. vol 4,Mycoplasma pathogenicity. Orlando: Academic Press; 1985. Pathogenicity factors in mycoplasmas and spiroplasmas; p. 313. [Google Scholar]
  • 15.Gallily R, Gifford GE, Loewenstein J. Suppression of both macrophage-mediated tumor cell lysis and cytolytic factor producion by a factor (CIF) derived from normal embryonic fibroblasts. Cancer Immunol Immunother. 1986;23:60. doi: 10.1007/BF00205557. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Hayflick L. Tissue cultures and mycoplasmas. Tex Rep Biol Med. 1965;23:285. [PubMed] [Google Scholar]
  • 17.Hibbs JB., Jr Evidence for activation of macrophages and modification of target cells byin vitro association with mycoplasmas. Clin Res. 1973;21:212. [Google Scholar]
  • 18.Johnson WJ, Balish E. Tumor-cytotoxic activity of resident rat macrophages. J Reticuloendothel Soc. 1981;29:369. [PubMed] [Google Scholar]
  • 19.Kettelhut IC, Fiers W, Goldberg AL. The toxic effects of tumor necrosis factor in vivo and their prevention by cyclooxygenase inhibitors. Proc Natl Acad Sci USA. 1987;84:4273. doi: 10.1073/pnas.84.12.4273. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Loewenstein J, Gallily R. Tissue culture and research. Budapest: Akademia Kiado, Publishing house of the Hungarian Academy of Sciences; 1984. Resistance of M109 lung adenocarcinoma cells to cytolysis by activated macrophages; p. 385. [Google Scholar]
  • 21.Loewenstein J, Rottem S, Gallily R. Induction of macrophage-mediated cytolysis of neoplastic cells by mycoplasmas. Cell Immunol. 1983;77:290. doi: 10.1016/0008-8749(83)90029-1. [DOI] [PubMed] [Google Scholar]
  • 22.Loewenstein J, Ben-Av P, Stein I, Gallily R. Intracellular production and extracellular release of TNF: induction byMycoplasma orale and LPS, and suppression by CIF. Immunobiology. 1987;175:114. [Google Scholar]
  • 23.Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951;193:265. [PubMed] [Google Scholar]
  • 24.Männel DN, Moore RN, Mergenhagen SE. Macrophages as a source of tumoricidal activity (tumor necrotizing factor) Infect Immun. 1980;30:523. doi: 10.1128/iai.30.2.523-530.1980. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Nissen-Meyer J, Austguten R, Espevik T. Comparison of recombinant tumor necrosis factor and the monocytederived cytotoxic factor involved in monocyte-mediated cytotoxicity. Cancer Res. 1987;47:2251. [PubMed] [Google Scholar]
  • 26.Old LJ. Tumor necrosis factor. Science. 1985;230:630. doi: 10.1126/science.2413547. [DOI] [PubMed] [Google Scholar]
  • 27.Razin S, Rottem S. Biochemical analysis of membranes. London: Chapman and Hall; 1970. Techniques for the manipulation of mycoplasma membranes; p. 3. [Google Scholar]
  • 28.Ruco LP, Meltzer MS. Defective tumoricidal capacity of macrophages from C3H/HeJ mice. J Immunol. 1978;120:422. [PubMed] [Google Scholar]
  • 29.Ruddle NH. Tumor necrosis factor and related cytotoxins. Immunol Today. 1987;8:129. [Google Scholar]
  • 30.Sayers TJ, Macher I, Cheeng J, Kagler E. The production of tumor necrosis factor by murine bone marrow-derived macrophages in response to bacterial lipopolysaccharide and a chemically synthesized monosaccharide precursor. J Immunol. 1987;138:2935. [PubMed] [Google Scholar]
  • 31.Smith PF, Longworthy TA, Mayberry WR. Distribution and composition of lipopolysaccharide from mycoplasmas. J Bacteriol. 1976;125:916. doi: 10.1128/jb.125.3.916-922.1976. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Taylor-Robinson D, Schorlemmer HU, Furr PM, Allison AC. Macrophage secretion and the complement cleavage product C3a in the pathogenesis of infections by mycoplasmas and L-forms of bacteria and in immunity to these organisms. Clin Exp Immunol. 1978;33:486. [PMC free article] [PubMed] [Google Scholar]
  • 33.Watson J, Kelly K, Largen M, Taylor BA. The genetic mapping of a defective LPS response gene in C3H/HeJ mice. J Immunol. 1978;120:422. [PubMed] [Google Scholar]
  • 34.Weinberg JB, Smith PF, Kahane I. Bacterial lipopolysaccharide and mycoplasmal lipoglycans. A comparison between their ability to induce macrophage-mediated tumor cell killing and limulus lysate clotting. Biochem Biophys Res Commun. 1980;97:493. doi: 10.1016/0006-291x(80)90290-9. [DOI] [PubMed] [Google Scholar]

Articles from Cancer Immunology, Immunotherapy : CII are provided here courtesy of Springer

RESOURCES